Trial Profile
Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Feb 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Bladder cancer; Cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms ST-ICI
- 15 Feb 2023 Status changed from active, no longer recruiting to completed.
- 26 Apr 2021 Planned End Date changed from 30 Jun 2023 to 30 Dec 2024.
- 26 Apr 2021 Status changed from recruiting to active, no longer recruiting.